Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

Kidney Cancer Clinical Trial

Official title:

Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00853021
• Other study ID #: CASE8804
• Secondary ID: P30CA043703CASE8
• Status: Completed
• Phase: Phase 2
• Start date: December 2005
• Est. completion date: October 2009

Study information

• Verified date: May 2019
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Biological therapies, such as aldesleukin, may stimulate the immune system in different ways and stop tumor cells from growing. Giving bevacizumab together with aldesleukin may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving bevacizumab together with aldesleukin works in treating patients with metastatic clear cell carcinoma of the kidney.

Description:

OBJECTIVES:

Primary

• To evaluate the effect of the combination of bevacizumab and aldesleukin on progression-free survival of patients with good- or intermediate-risk metastatic clear cell renal cell carcinoma.

Secondary

• To determine the objective response rate in patients receiving this regimen.

• To determine the time to progression in patients receiving this regimen.

• To evaluate immunomodulatory effects of this regimen in patients

• To evaluate the toxicity of this regimen in these patients.

OUTLINE: Patients receive bevacizumab IV over 30-90 minutes on days -14, 1, 15, 29, and 42 and aldesleukin subcutaneously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving complete response after completion of study therapy may receive 1 additional course of therapy.

After completion of study therapy, patients are followed periodically.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: October 2009
• Est. primary completion date: October 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed renal cell carcinoma (RCC) of clear cell histology with or without sarcomatoid features

• Metastatic disease

• No non-clear cell RCC (i.e., papillary, collecting-duct, or chromophobe)

• Good- or intermediate-risk category as defined by having = 2 of the following factors:

• No prior nephrectomy

• Karnofsky performance status < 80%

• Hemoglobin < 12 g/dL

• Corrected calcium > 10.0 mg/dL

• LDH > 1.5 times upper limit of normal (ULN)

• Must have undergone a nephrectomy at least 28 days ago

• Measurable or evaluable disease by RECIST

• No significant effusions and/or ascites

• No prior or concurrent brain or CNS metastasis

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• Life expectancy of = 3 months

• WBC = 3,000/mm^3

• Platelet count = 100,000/mm^3

• Hemoglobin = 9.5 g/dL

• Creatinine = 2.0 mg/dL

• Total bilirubin = 1.5 mg/dL

• AST = 5.0 times ULN

• Alkaline phosphatase = 2.5 times ULN (= 10 times ULN with bone metastasis)

• Calcium = 12 mg/dL

• Urine protein:creatinine ratio = 1.0

• INR = 1.5 (unless receiving warfarin therapy)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No uncontrolled seizure disorder

• No known HIV positivity

• No local or systemic infections requiring IV antibiotics within the past 28 days

• No significant traumatic injury in the past 28 days

• No serious non-healing wound, ulcer, or acute bone fracture

• No evidence of bleeding diathesis or coagulopathy

• No other malignancy except basal cell or squamous cell carcinoma of the skin, carcinoma in-situ of the uterine cervix, or any malignancy treated with curative intent and in complete remission for > 3 years

• No history of serious systemic or severe cardiovascular disease, including any of the following:

• Arterial thromboembolic event (including transient ischemic attack)

• Cerebrovascular accident

• Unstable angina

• Myocardial infarction within the past 6 months

• Uncontrolled hypertension (BP > 160/110 mm Hg on medication)

• Uncontrolled cardiac arrhythmia

• Congestive heart failure

• Angina pectoris

• NYHA class III-IV cardiovascular disease

• Peripheral vascular disease = grade II

• No history of abdominal fistula and/or bowel or gastric perforation within the past 6 months

• No history of other diseases, metabolic dysfunction, or physical or laboratory examination findings giving reasonable suspicion of a disease or condition that contraindicate the use of investigational drugs, or that might affect the interpretation of study results, or that render patient at high-risk for treatment complications

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior organ allografts

• No prior systemic therapy for metastatic clear cell renal cell carcinoma

• At least 4 weeks since prior radiotherapy and recovered

• Radiotherapy for control of pain from skeletal lesions allowed within the past 28 days

• More than 12 months since prior adjuvant therapy

• More than 7 days since prior fine-needle aspirations or core biopsies

• More than 28 days since prior and no concurrent major surgery requiring general anesthesia or open biopsy

• No concurrent aspirin, corticosteroids (except at replacement doses), barbiturates, or other investigational agents

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms

Intervention

Biological:
• aldesleukin
SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
• bevacizumab
Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.

Locations

Country	Name	City	State
United States	Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center	Cleveland	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Jorge A. Garcia, MD	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Peripheral Blood CD1c+ Myeloid Dendritic Cells	Peripheral blood mononuclear cells (PBMC) and plasma were separated by centrifugation. Targeted cells were isolated by a magnetic labeling system. Total RNA was isolated and then amplified by (Polymerase Chain Reactions) PCR to measure levels of the immune parameter.	Baseline (day -14), Beginning and end of cycle 1 (day 1, 57)
Other	CD303+ Plasmacytoid Dendritic Cells	Peripheral blood mononuclear cells (PBMC) and plasma were separated by centrifugation. Targeted cells were isolated by a magnetic labeling system. Total RNA was isolated and then amplified by (Polymerase Chain Reactions) PCR to measure levels of the immune parameter.	Baseline (day -14), beginning and end of cycle 1 (day 1, 57)
Other	IL-8 Levels	Peripheral blood mononuclear cells (PBMC) and plasma were separated by centrifugation. Targeted cells were isolated by a magnetic labeling system. Total RNA was isolated and then amplified by (Polymerase Chain Reactions) PCR to measure levels of the immune parameter.	Baseline (day -14), beginning and end of cycle 1 (day 1, 57)
Other	CD4+ Treg Cells	Peripheral blood mononuclear cells (PBMC) and plasma were separated by centrifugation. Targeted cells were isolated by a magnetic labeling system. Total RNA was isolated and then amplified by (Polymerase Chain Reactions) PCR to measure levels of the immune parameter.	Baseline (day -14), beginning and end of cycle 1 (day 1, 57)
Other	CD25+ Treg Cells	Peripheral blood mononuclear cells (PBMC) and plasma were separated by centrifugation. Targeted cells were isolated by a magnetic labeling system. Total RNA was isolated and then amplified by (Polymerase Chain Reactions) PCR to measure levels of the immune parameter.	Baseline (day -14), beginning and end of cycle 1 (day 1, 57)
Other	T-helper Cells (Type 1,2)	Peripheral blood mononuclear cells (PBMC) and plasma were separated by centrifugation. Targeted cells were isolated by a magnetic labeling system. Total RNA was isolated and then amplified by (Polymerase Chain Reactions) PCR to measure levels of the immune parameter.	Baseline (day -14), beginning and end of cycle 1 (day 1, 57)
Primary	Progression Free Survival	Progression free survival is defined as the time between registration and progression of disease as defined by the RECIST criteria where there is a 20% increase in the diameter of the tumor and at least a 5mm absolute increase in diameter.	From baseline (day -14) to disease progression (reported at 2 years)
Secondary	Objective Response Rate (Complete and Partial Response)	Objective response rate to be assigned a status of PR or CR per RECIST criteria, with Complete Response (CR) referring to the disappearance of all target lesions, Partial Response (PR) referring to at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.; Changes in tumor measurements must be confirmed by repeat assessments that should be performed no less than 4 weeks after the criteria for response are first met.	4 weeks after end of treatment
Secondary	Percentage of Patients With Constitutional Adverse Events	Toxicity Criteria: The NCI graded common clinical toxicity scale (NCI Version 2.0) will be employed to grade observed toxicity of fatigue and fever/chills	From start of treatment to 30 days after treatment
Secondary	Percentage of Patients With Neutropenia	Toxicity Criteria: The NCI graded common clinical toxicity scale (NCI Version 2.0) will be employed to grade observed toxicity of neutropenia	From start of treatment to 30 days after treatment